DMK
TRIL

David M. Knott’s Trillium Therapeutics Inc. TRIL Stock Holding History

David M. Knott’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3.49M Hold
198,699
– – 1.27% 21
2021
Q2 		$1.93M Hold
198,699
– – 0.68% 43
2021
Q1 		$2.13M Buy
198,699
+24,000
+14% +$297K 0.91% 32
2020
Q4 		$2.57M Sell
174,699
-1,516
-0.9% -$21.9K 1.16% 25
2020
Q3 		$2.5M Sell
176,215
-88,010
-33% -$877K 1.47% 16
2020
Q2 		$2.14M Buy
264,225
+127,725
+94% +$790K 1.17% 22
2020
Q1 		$551K Buy
+136,500
New +$516K 0.35% 45

Other funds holding TRIL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

David M. Knott's TRIL Position: Q3 2021 in Review

David M. Knott held its Trillium Therapeutics Inc. (TRIL) position steady in Q3 2021 at 198,699 shares worth $3.49M. The position accounts for 1.27% of the portfolio, ranked #21.

David M. Knott first reported a position in TRIL in Q1 2020 and has held it in 7 quarters since. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • David M. Knott held 198,699 shares of Trillium Therapeutics Inc. worth $3.49M as of Q3 2021.
  • David M. Knott left its Trillium Therapeutics Inc. share count unchanged in Q3 2021.
  • Trillium Therapeutics Inc. made up 1.27% of David M. Knott's portfolio in Q3 2021, its #21 holding.
  • David M. Knott first reported a position in Trillium Therapeutics Inc. in Q1 2020 and has held it in 7 quarters since.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on David M. Knott's 13F filing for Q3 2021, filed 12 Nov 2021.